News WntResearch AB

Equities

WNT

SE0022239901

End-of-day quote Nasdaq Stockholm Other stock markets 04:30:00 31/01/2024 am IST			5-day change	1st Jan Change
6.7 ^SEK	-.--%		-.--%	-27.17%

03/05	WntResearch AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
29/02	WntResearch AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

WntResearch : Presentationen från AGM.	27/05	PU
WntResearch's CEO to BioStock: "If the effect is confirmed, there are good opportunities for licensing agreements next year"	08/05	AQ
WntResearch AB Reports Earnings Results for the First Quarter Ended March 31, 2024	03/05	CI
BioStock: WntResearch's new CEO comments on his first month in the position	02/04	AQ
Resigning WntResearch CEO tells BioStock: "It will be exciting to follow!"	01/03	AQ
WntResearch AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	29/02	CI
WntResearch AB Reports Earnings Results for the Full Year Ended December 31, 2023	29/02	CI
WntResearch initiates collaboration with Business Sweden with the goal of establishing commercial partnerships for Foxy-5 in Japan and South Korea	26/02	AQ
WntResearch Initiates Collaboration with Business Sweden with the Goal of Establishing Commercial Partnerships for Foxy-5 in Japan and South Korea	26/02	CI
WntResearch continues to the next step in the phase 2 study NeoFox with the highest evaluated dose of Foxy-5	12/02	AQ
WntResearch AB Continues to the Next Step in the Phase 2 Study Neofox with the Highest Evaluated Dose of Foxy-5	12/02	CI
WntResearch announces the last day for trading in BTU and the first day for trading in warrants series TO 7 and warrants series TO 8	08/02	AQ
WntResearch carries out a directed issue of units to underwriters in connection with the completed rights issue	08/02	AQ
WntResearch publishes outcome in rights issue	01/02	AQ
WntResearch's co-founder applies for subscription of additional units in the ongoing rights issue with a last day for subscription on 29 January 2024	24/01	AQ
WntResearch Announces CEO Changes	10/01	CI
WntResearch publishes prospectus in connection with rights issue	08/01	AQ
Bulletin from the extraordinary general meeting in Wntresearch AB on 22 December 2023	22/12	AQ
WntResearch continues to the second dose group in clinical proof of concept study of Foxy-5	06/12	AQ
WntResearch Continues to the Second Dose Group in Clinical Proof of Concept Study of Foxy-5	06/12	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News WntResearch AB

Equities

WNT

SE0022239901

Summary

Filters